Vertex Pharmaceuticals
E387617
Vertex Pharmaceuticals is a biotechnology company best known for developing transformative therapies for cystic fibrosis and other serious diseases using a precision medicine approach.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Vertex Pharmaceuticals canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T3803131 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Vertex Pharmaceuticals Context triple: [Stuart L. Schreiber, coFounderOf, Vertex Pharmaceuticals]
-
A.
Alkermes
Alkermes is a biopharmaceutical company that develops innovative medicines for central nervous system disorders and other serious chronic diseases.
-
B.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
C.
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics using antisense technology.
-
D.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
E.
Eli Lilly and Company
Eli Lilly and Company is a major American pharmaceutical corporation known for developing and manufacturing a wide range of prescription medicines, including treatments for diabetes, cancer, and mental health disorders.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Vertex Pharmaceuticals Target entity description: Vertex Pharmaceuticals is a biotechnology company best known for developing transformative therapies for cystic fibrosis and other serious diseases using a precision medicine approach.
-
A.
Alkermes
Alkermes is a biopharmaceutical company that develops innovative medicines for central nervous system disorders and other serious chronic diseases.
-
B.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
C.
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics using antisense technology.
-
D.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
E.
Eli Lilly and Company
Eli Lilly and Company is a major American pharmaceutical corporation known for developing and manufacturing a wide range of prescription medicines, including treatments for diabetes, cancer, and mental health disorders.
- F. None of above. chosen
Statements (53)
| Predicate | Object |
|---|---|
| instanceOf |
biotechnology company
ⓘ
pharmaceutical company ⓘ public company ⓘ |
| brandName |
Kalydeco
ⓘ
Orkambi ⓘ Symdeko ⓘ Trikafta ⓘ |
| collaboratesWith |
CRISPR Therapeutics
ⓘ
Moderna ⓘ Obsidian Therapeutics ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| develops |
cell therapies
ⓘ
gene-editing therapies ⓘ small-molecule drugs ⓘ |
| focusesOn |
cystic fibrosis
ⓘ
precision medicine ⓘ serious diseases ⓘ |
| formerHeadquartersLocation |
Cambridge, Massachusetts
ⓘ
surface form:
Cambridge, Massachusetts, United States
|
| foundedBy |
Joshua Boger
ⓘ
Kevin J. Kinsella ⓘ |
| foundedIn |
Greater Boston
ⓘ
surface form:
Boston metropolitan area
|
| hasClinicalProgram |
VX-264
ⓘ
VX-548 ⓘ VX-880 ⓘ exagamglogene autotemcel ⓘ |
| hasOfficeIn |
London, England
ⓘ
surface form:
London, United Kingdom
Munich ⓘ
surface form:
Munich, Germany
Oxford ⓘ
surface form:
Oxford, United Kingdom
Paris ⓘ
surface form:
Paris, France
|
| hasResearchFacilityIn |
Boston, Massachusetts
ⓘ
surface form:
Boston, Massachusetts, United States
San Diego, California, United States ⓘ |
| headquartersLocation |
Boston, Massachusetts
ⓘ
surface form:
Boston, Massachusetts, United States
|
| inception | 1989 ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| knownFor |
precision medicine approach
ⓘ
transformative therapies for cystic fibrosis ⓘ |
| listedOn | NASDAQ ⓘ |
| notableProduct |
elexacaftor/tezacaftor/ivacaftor
ⓘ
ivacaftor ⓘ lumacaftor/ivacaftor ⓘ tezacaftor/ivacaftor ⓘ |
| regulatoryApprovalFor |
Kalydeco
ⓘ
Orkambi ⓘ Symdeko ⓘ Trikafta ⓘ |
| specializesIn | CFTR modulators ⓘ |
| therapeuticArea |
beta thalassemia
ⓘ
cystic fibrosis ⓘ pain ⓘ sickle cell disease ⓘ type 1 diabetes ⓘ |
| tickerSymbol | VRTX ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Vertex Pharmaceuticals Description of subject: Vertex Pharmaceuticals is a biotechnology company best known for developing transformative therapies for cystic fibrosis and other serious diseases using a precision medicine approach.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.